Tag Archives: Charlotte Lozier Institute
The decision striking down Roe v. Wade has led to shrill outcries by providers of in vitro fertilization & surrogacy. Both are lucrative, high-growth commercial industries enjoying increasing demand, thanks in part to rising infertility & late pregnancy among folk in income brackets able to pay for these services. Many of those involved in this industry are alarmed that their “market growth” & profitability are threatened by abortion restrictions & are willing to publicly say so.
Sometimes you hear of an event, experience a situation, or even meet a person who really convicts you about something, and then you feel you have to tell others about it even though you haven’t mastered it yourself yet. That is just what happened to me in the recent past, so I'm writing this article to myself as much as to you.
Attorneys general of 23 states have filed two amicus briefs in support of a lawsuit seeking the withdrawal of FDA approval of the drugs mifepristone (RU-486) and misoprostol for use in chemical abortions. Unfortunately, Illinois Attorney General Kwame Raoul is not one of them. Success in this suit could make chemical abortion illegal even in states where abortion access remains legal.
In just a few short months, the U.S. Supreme Court will be handing down their decision in Dobbs v. Jackson Women’s Health Organization, determining the constitutionality of a 2018 Mississippi law prohibiting women from accessing abortions after 15 weeks of pregnancy. This case is expected to determine the fate of Roe v. Wade, the infamous 1973 U.S. Supreme Court ruling preventing states from unduly restricting abortions before the point of viability.
With the number of deaths in the U.S. officially attributed to COVID-19 (defined by the CDC as anyone who died with COVID-19, though not necessarily because of it) now around 230,000 and a surge in the number of COVID-19 cases throughout the U.S. over the past few weeks, a growing sense of urgency has been created for a COVID-19 vaccine. Several companies are developing what are said to be promising vaccine candidates, and HHS Secretary Alex Azar said earlier this week that a vaccine should be ready for the most vulnerable subgroups by the end of this year.